| Market Cap | 19.79M | P/E | - | EPS this Y | -2.40% | Ern Qtrly Grth | - |
| Income | -37.58M | Forward P/E | -0.60 | EPS next Y | 32.10% | 50D Avg Chg | 8.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -23.00% |
| Dividend | N/A | Price/Book | 0.47 | EPS next 5Y | - | 52W High Chg | -73.00% |
| Recommedations | 3.00 | Quick Ratio | 3.25 | Shares Outstanding | 53.94M | 52W Low Chg | 48.00% |
| Insider Own | 6.07% | ROA | -45.11% | Shares Float | 35.45M | Beta | 1.19 |
| Inst Own | 12.13% | ROE | -87.13% | Shares Shorted/Prior | 419.98K/240.62K | Price | 0.37 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 201,161 | Target Price | 1.25 |
| Oper. Margin | - | Earnings Date | Nov 13 | Volume | 64,550 | Change | 3.89% |
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania. As of October 10, 2023, Zynerba Pharmaceuticals, Inc. operates as a subsidiary of Harmony Biosciences Holdings, Inc.
| Canaccord Genuity | Hold | Aug 16, 23 |
| HC Wainwright & Co. | Neutral | Aug 15, 23 |
| Canaccord Genuity | Buy | Jun 23, 22 |
| Needham | Hold | Jul 1, 20 |
| Cantor Fitzgerald | Overweight | May 28, 20 |
| Needham | Buy | Oct 21, 19 |
| Roth Capital | Buy | Apr 30, 19 |
| Cantor Fitzgerald | Overweight | Sep 21, 18 |
| Canaccord Genuity | Buy | Aug 3, 18 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Sebree Terri B | President President | Jan 23 | Sell | 0.6 | 24,661 | 14,797 | 343,204 | 01/25/23 |
| Fickenscher James E | Chief Financial Offi.. Chief Financial Officer | Jan 23 | Sell | 0.6 | 17,769 | 10,661 | 154,736 | 01/25/23 |
| Rosenberger Brian | VP, Commercial & Bus.. VP, Commercial & Business Dev. | Jan 23 | Sell | 0.6 | 12,663 | 7,598 | 94,848 | 01/25/23 |
| ANIDO ARMANDO | Chairman & Chief Exe.. Chairman & Chief Exec. Officer | Jan 23 | Sell | 0.6 | 35,453 | 21,272 | 576,235 | 01/25/23 |
| Sebree Terri B | President President | Jul 18 | Sell | 1.1 | 8,281 | 9,109 | 367,865 | 07/20/22 |
| Rosenberger Brian | VP, Commercial & Bus.. VP, Commercial & Business Dev. | Jul 18 | Sell | 1.1 | 4,289 | 4,718 | 107,511 | 07/20/22 |
| Fickenscher James E | Chief Financial Offi.. Chief Financial Officer | Jul 18 | Sell | 1.1 | 6,013 | 6,614 | 172,505 | 07/20/22 |
| ANIDO ARMANDO | Chairman & CEO Chairman & CEO | Jul 18 | Sell | 1.1 | 11,899 | 13,089 | 611,688 | 07/20/22 |
| KISNER DANIEL L | Director Director | Jun 14 | Sell | 1.01 | 40 | 40 | 28,069 | 06/16/22 |
| FEDERICI WILLIAM J | Director Director | Jun 14 | Sell | 1.01 | 40 | 40 | 28,069 | 06/16/22 |
| Stephenson Pamela | Director Director | Jun 14 | Sell | 1.01 | 40 | 40 | 28,069 | 06/16/22 |
| MOCH KENNETH I | Director Director | Jun 14 | Sell | 1.01 | 40 | 40 | 28,069 | 06/16/22 |
| COOPER WARREN D | Director Director | Jun 14 | Sell | 1.01 | 40 | 40 | 28,069 | 06/16/22 |
| Butler John P. | Director Director | Jun 14 | Sell | 1.01 | 53 | 54 | 33,056 | 06/16/22 |